SI
SI
discoversearch

Biotech / Medical
Provectus Pharmaceuticals Inc.
An SI Board Since April 2006
Posts SubjectMarks Bans Symbol
13017 109 0 PVCT
Emcee:  Jack Russell Type:  Moderated



This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.

Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:

PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.

Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.

PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.

Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.

Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read detailed Research Reports

------------------------------------------------------------------------------------------------------------------------------------------------------

Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.

The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com. The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.

-------------------------------------------------------------------------------------------------------------------------------------------------------



Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com

August 19, 2008
PV-10 for Melanoma Story Airs on ABC's 7:30 Report in Australia
The 7:30 Report, a highly acclaimed ABC current affairs program airing in Australia, recently ran a story on the treatment of melanoma with PV-10.
pvct.com




PVCT on YouTube...
youtube.com

theze.cn

--------------------------------------------------------------

PVCT insiders transactions:
secform4.com

--------------------------------------------------------------


Contact Info

Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302


Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com


Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com


Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031



--------------------------------------------------------------
Company Website


pvct.com

==============================================================
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
13017BBC Cancer in China... bbc.comJack Russell-November 17
13016Hi Jack, Could you please upload a logo into the logo field on your board? IfSI Ron (Hall Monitor)-November 13
13015This is an unfortunate protocol for PV-10NTTG-November 13
13014NEWS -- Provectus Biopharmaceuticals’ Protocol for Phase 3 Study Of PV-10 As TreJack Russell-November 13
13013Cost Of Skin Cancer Treatment Increasing Rapidly In The US. The Washington Pboomertree2-November 11
13012PVCT's follow-up PR ...... Provectus Biopharmaceuticals Announces Abstract Howard Williams-November 6
13011Efficacy of intralesional injection with PV-10 in combination with co-inhibitoryboomertree2-November 6
13010November 06, 2014 06:00 AM Eastern Standard Time KNOXVILLE, Tenn.--( BUSINESHoward Williams-November 6
13009Wide-ranging PV-10 article in Medscape today http://www.medscape.com/viewarticlHoward Williams2October 31
13008Forbes article... To me this is big news. Not so much the content but who publisJack Russell-October 30
13007SEC Insider-Trading Probe Centers On CMS. The Wall Street Journal (10/29, A1,boomertree2-October 29
13006Could it be the FDA panders to big pharma? doing what they want including stalliJack Russell-October 28
13005Those articles appear to be contrary to what the FDA has told PVCT. A bit baffliKhris Smith-October 27
13004Analysis: Most Cancer Medications Approved With No Proof That They Extend Life. boomertree2-October 27
13003Assume most of you have read or will read Alan Ross' latest post about how fLittlebits-October 21
13002Howard good point. Yet we haven't seen a PR officially announcing it. I beMark Buczynski-October 17
13001[Poll]FortStCowboy-October 10
13000I missed these words in my original posting of today's news. IMO these are Howard Williams-October 3
12999Provectus News Cutaneous, Locoregional Melanomas Show High, Rapid Responses toHoward Williams-October 3
12998Immunotherapy Given Breakthrough Status In Melanoma. In continuing coverage, boomertree2-October 3
12997Provectus Biopharmaceuticals' PV-10 Clinical Data on Melanoma Now Available Howard Williams-September 24
12996Merck Faces Lawsuit Over Melanoma Immunotherapy Patent. The Wall Street Journboomertree2-September 8
12995FDA Approves 27 New Medicines So Far This Year, Same Number As All Of 2013. Thboomertree2-September 8
12994FDA Approves New Immunotherapy For Melanoma. There was wide coverage of the newboomertree2-September 5
12993Sinopharm Starts Talks With Provectus Over Anticancer Thursday August 28, 2014 Howard Williams-August 28
12992PVCT a breakout buy? thestreet.comHoward Williams-August 22
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.